Pfizer has secured an exclusive option to acquire Western Oncolytics’ WO-12 once the oncolytic vaccinia virus has completed Phase I.

Almost all of the biotech IPOs that have priced since the first quarter have broken issue, meaning that they are now trading below their offer price

Gene editing biotech Editas Medicine has signed a three-year R&D collab deal with Milan-based San Raffaele Telethon Institute for Gene Therapy to develop…

In our EuroBiotech roundup this week, Motif Bio sets IPO terms, MSP plans a £60 million laboratory development, Prokarium bags cash for plague R&D and more.

AstraZeneca has dropped 6 drug programs from its pipeline--with almost all the early-stage candidates being axed from its MedImmune biologics arms--in what is…

Genmab and J&J bag a breakthrough designation, Merck dumps ALK, uniQure yo-yos on gene therapy data and more.

Shares in uniQure briefly hit a new low following a negative knee-jerk reaction to fresh data on its hemophilia B gene therapy.

BioMarin Pharmaceutical gained almost $1 billion in market cap on strong positive data for its gene therapy to treat severe hemophilia A.